

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7339004

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	NOVARTIS AG	06/27/2016
	GLYKOS FINLAND OY	06/30/2016
RECEIVING PARTY DATA		
Name:	GLYKOS FINLAND OY	
Street Address:	VIIKINKAARI 6	
City:	HELSINKI	
State/Country:	FINLAND	
Postal Code:	00790	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17529931
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	ip@remotedocket.com	
Correspondent Name:	PATRICK J. HALLORAN	
Address Line 1:	3141 MUIRFIELD ROAD	
Address Line 4:	CENTER VALLEY, PENNSYLVANIA 18034	
ATTORNEY DOCKET NUMBER:	NOVA-0002-WO-US-CON4	
NAME OF SUBMITTER:	PATRICK J. HALLORAN	
SIGNATURE:	/Patrick J. Halloran/	
DATE SIGNED:	05/19/2022	
Total Attachments: 6		
source=7-NOVA0002-NOVAG-GLYKOS-X#page1.tif		
source=7-NOVA0002-NOVAG-GLYKOS-X#page2.tif		
source=7-NOVA0002-NOVAG-GLYKOS-X#page3.tif		
source=7-NOVA0002-NOVAG-GLYKOS-X#page4.tif		
source=7-NOVA0002-NOVAG-GLYKOS-X#page5.tif		
source=7-NOVA0002-NOVAG-GLYKOS-X#page6.tif		

ASSIGNMENT

This Assignment Agreement is entered into by and between NOVARTIS AG, a Swiss corporation with its principal offices at Lichtstrasse 35, 4056 BASEL, SWITZERLAND (hereafter "NOVARTIS") and GLYKOS FINLAND OY, a limited liability company whose address is Viikinkaari 6, 00790 Helsinki, Finland (hereafter "ILMO").

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, NOVARTIS AG and GLYKOS FINLAND OY do hereby sell, assign and transfer to GLYKOS FINLAND OY (hereinafter referred to as the "ASSIGNEE") and its successors, assigns and legal representatives, all of NOVARTIS' and GLYKOS' right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) and patents listed in Exhibit Q;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the name of ASSIGNEE or its designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by NOVARTIS and GLYKOS if this sale, assignment and transfer had not been made.

NOVARTIS and GLYKOS hereby authorize ASSIGNEE and its representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

NOVARTIS and GLYKOS hereby covenant and agree that they will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 27th day of June, 2016.

NOVARTIS AG

Authorized signatory

BY  Authorized signatory
Tanja Vogel-S.

Nihan Corakci
Nihan CORAKCI

Print Name: Title:


Authorized signatory

Witness 

Print Name GREBOIRE COMYN.

Authorized signatory

Witness MARIA DE LOS DESAHUADOS, LAMORRE SILVESTRE

Print Name 

Executed this 30 day of June, 2016.


GLYKOS FINLAND OY

BY  LS.

Print Name: Title: Juhani Saarinen, CEO

Witness 

Print Name Jari Helin

Witness 

Print Name Annamari Heiskanen

EXHIBIT Q

PROTEASE DEFICIENT FILAMENTOUS FUNGAL CELLS AND METHODS OF USE THEREOF

Priority: US 61/583559, filed on 5.1.2012

PCT/EP2013/050126, filed on 4.1.2013 (WO/2013/102674)

Country/Convention	Appl. No.
US	14/370255
EP	13700021.2
JP	2014-550709
CN	201380012940.6
AU	2013207165
KR	10-2014-7021955
IL	233052
MX	MX/A/2014/008272
BR	1120140165874
IN	4905/DELNP/2014
SG	11201403818X
CA	2861697
RU	2014132178

PRODUCTION OF FUCOSYLATED GLYCOPROTEINS

Priority: US61/650910, filed 23.5.2012

PCT/EP2013/060627, filed 23.5.2013 (WO/2013/174927)

Country/Convention	Appl. No.
EP	13725617.8
US	14/402837

O-mannosyltransferase Deficient Filamentous Fungal Cells and Methods of Use Thereof

Priority: EP13175141.4, filed on 4.7.2013

PCT/EP2014/064248, filed 3.7.2014 (WO/2015/001049)

Country/Convention	Appl. No.
US	14/902492
EP	14734515.1
CN	201480048205.5
KR	10-2015-7036975
MX	MX/A/2016/000128
BR	112015032695-1
IN	201617003642
SG	11201510814Y
CA	2916594
RU	2016103373

MULTIPLE PROTEASES DEFICIENT FILAMENTOUS FUNGAL CELLS AND METHODS OF USE THEREOF

Priority: EP13176001.9, filed on 10.7.2013

PCT/EP2014/064820, filed 10.7.2014 (WO/2015/004241)

Country/Convention	Appl. No.
US	14/903673
EP	14738497.8
CN	201480049741.7
AU	2014289183
KR	10-2016-7003460
MX	MX/A/2016/000306
BR	112016000394-2
IN	201617004494

SG	112016001158
CA	2916905
RU	2016104064
JP	2016-524825
IL	243276

PRODUCTION OF GLYCOPROTEINS HAVING INCREASED N-GLYCOSYLATION SITE OCCUPANCY

Priority: EP13175997.9, filed on 10.7.2013

PCT/EP2014/064818, filed 10.7.2014 (WO/2015/004239)

Country/Convention	Appl. No.
US	14/903610
EP	14738496.0
CA	2916899
CN	201480039008.7
IN	201617003635
SG	11201600098R

PRODUCTION OF GLYCOPROTEINS WITH MAMMALIAN-LIKE N-GLYCANS IN FILAMENTOUS FUNGI

Priority: EP14177875.3, filed 21.7.2014

Country/Convention	Appl. No.	Filed	Publ. No.
PCT	PCT/EP2015/066686	21.7.2015	WO/2016/012468